[Androgenic treatment with depot mesterolone in dyspermia].
The clinical use of testosterone, and more recently of orally administered mesterolone in disorders of male fertility is of limited therapeutic efficacy, as shown by data found in the literature. On the basis of these considerations, the authors have tested mesterolone cyclopentylproprionate in 15 subjects suffering from sperm disorders. The drug, which is slowly released in the tissues has been parenterally administered at a total dose of 1,200 mg (100 mg per week). During the therapeutic trial the following aspects have been studied: spermiologic and hormonal patterns, general conditions, libido, principal organic functions and the possible side effects. Results are critically evaluated.
D000328:Adult; D002452:Cell Count; D002986:Clinical Trials as Topic; D013196:Dihydrotestosterone / Q000031:analogs & derivatives*; D004341:Drug Evaluation; D004542:Ejaculation; D004958:Estradiol / Q000097:blood; D005640:Follicle Stimulating Hormone / Q000097:blood; D006065:Gonadotropins, Pituitary / Q000627:therapeutic use; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007248:Infertility, Male / Q000188:drug therapy*; D007989:Libido / Q000187:drug effects; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008655:Mesterolone / Q000627:therapeutic use; D008875:Middle Aged; D013081:Sperm Motility / Q000187:drug effects; D013091:Spermatogenesis; D013094:Spermatozoa; D013739:Testosterone / Q000097:blood; D014783:Viscosity
D006065:Gonadotropins, Pituitary; D013196:Dihydrotestosterone; D008655:Mesterolone; D013739:Testosterone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone